TBVI symposium: Update on TB vaccine development

29-01-13

Les Diablerets - Switzerland

What is the current progress in TB vaccine development? To answer this question, TBVI brings together internationally renowned scientists. The symposium is open to everyone and coinsides with TBVI's annual project meeting in Les Diablerets, Switzerland.  The meeting will take place in Maison des Congrès, Val-Neige, 1865 Les Diablerets , Phone +41 (0)24 492 36 19, Located in the heart of the village, only 5-10 minutes walk from all hotels in the village.

Programme:

15.00-16.20 Early TB vaccine development
Chair: Juhani Eskola (chair TBVI Steering Committee)

  • TB Vaccines that Induce Bactericidal Immunity – Michelle Larsen, Albert Einstein College of Medicine
  • The vaccine development portfolio at Aeras – Barry Walker, Aeras
  • Translational animal models for TB vaccines – Ann Williams, Health Protection Agency
  • Unbiased Definition of Immunodominant CD8+ Antigens in TB  - David Lewinsoh, Oregon Health & Science University


16.20-16.50 Break

17.10-19.10 TB vaccines in clinical development
Chair: Luc Hessel (Chair Clinical Development Team TBVI)

  • MVA85A, update on recent trials – Helen McShane, Oxford University
  • M72 vaccine development program – Stéphane Temmerman, GSK
  • H1/H56 – Peter Andersen, SSI
  • AdHu5Ag85A TB vaccine: current clinical development and future prospects   – Zhou Xing, McMaster University
  • VPM1002 TB Vaccine: A BCG replacement on the horizon - Leander Grode, VPM
  • Steps toward the development of MTBVAC - Carlos Martin, University of Zaragoza

 

For registration, please email Cora Agterdenbosch

TBVI will take care of coffee and tea. However, participants are required to take care of their own accomodation and meals. For hotels in Les Diablerets, click here.

 

Contact

Ms. Erna Balk
Director Advocacy & Communications
+31 320 277 552
erna.balk(at)tbvi.eu